Category Archives: Eczema

A WOMAN has been ravaged by a severe skin condition that leaves her oozing face stuck to the pillowcase.

Sedi Khumalo said her skin is so itchy that it feels like I need to scratch down to my bones.

4

4

The 28-year-old, from Worsley, Greater Manchester, says she's in constant pain after quitting oral steroids which helped treat her eczema.

She suffers with a condition known as topical steroid withdrawal (TSW), when the skin becomes worse after stopping medication.

TSW has had a devastating effect on Sedis mental health and even triggered thoughts of ending her own life.

Sedi claims she was on medication for over seven years and initially thought the pills were a miracle treatment as they cleared her eczema.

But she found that they made the condition worse over time. The flare-ups became more severe the more she took steroids.

The bank worker decided to go cold turkey on the creams and pills in October 2020.

She was stunned as she noticed her skin began to swell, crack and ooze as a result of the skin desperately needing the medication.

Sedi said: "Although this might look like eczema, it's not and it's important that people know that.

"Its addiction to prescription drugs and my body became so dependent on them and now it is learning to heal itself.

"I'm still trying to get my head around the condition.

"TSW gives me what is known as a 'bone itch' - my nerves are damaged from the steroids and when I'm itchy it can't be relieved and it feels like I need to scratch down to my bones."

At times, the only relief was a scalding hot bath or shower which isn't good for your skin either.

Sedi said she keeps going back to her GP who tries to treat her for eczema.

She said: "I was told by the GP it was severe eczema but I knew in myself it wasn't - I was quite scared because I thought my health in general was deteriorating.

They didn't realise the thing they were using to treat me was making me ill - it was really frustrating."

The National Eczema Association says that TSW is a serious potential side effect of topical steroid use that is not readily recognized by patients and providers.

Much is unknown about TSW, including how many people are affected and how much steroid medication use triggers it.

But it is clear that it occurs mostly with long-term use of the drugs, for example in people who have used creams to keep their eczema at bay since childhood.

Whilst her skin is in recovery mode, Sedi said that she couldn't leave her own home and the condition had a financial and severe mental impact on her daily life.

She added: "Since I've been in withdrawal, I've had panic attacks and experienced depression which I used to take antidepressants for.

"I wanted to end my own life and had to call the Samaritans to try to get help to manage the situation.

"It got so bad that I had to drop out of my studies and stop my part time job which had a financial impact.

"TSW can also mess with your hormones and cause insomnia - I was waking up several times in the night but I had no idea why. "

Now, Sedi is feeling slightly better and wants to raise awareness about TSW as she believes it is not a topic that is discussed enough.

She said: "Some people go through TSW for years - my body is healing from a steroid addiction and it needs to figure out how to heal itself again."

4

4

Go here to see the original:
My skin began to swell and ooze so much I woke up stuck to my pillowcase now my BONES itch... - The Sun

Advise patients to continue using emollients but to be aware of burn risks, avoid naked flames, and stop smoking

Emollients are not flammable themselves but, when impregnated into fabric, can act as an accelerant

People most at risk are those with reduced ability to react quickly when emollient impregnated fabric is exposed to naked flames

A 72 year old man with poor mobility, Parkinsons disease, and dementia attends the emergency department with upper body burns. He is a smoker and his carer applies emollients to most of his body daily as long term maintenance treatment for eczema. The attending clinician established that the patients burns were sustained when his cigarette came into contact with the right arm of his pyjamas, which quickly caught fire.

Emollients are an important treatment and generally safe; they are not flammable in themselves, in their container, or on the skin. However, awareness of fire riskfrom fabric that has become impregnated with emollient residueis low.123

Emollient can transfer from skin onto clothing, furniture, and bedding, which accumulates over timeeven with regular washing, some residue remains. A naked flame is needed for ignition. The residue acts as an accelerant, increasing the speed of ignition and intensity of a fire, reducing the time available to extinguish it.

Emollients are moisturising treatments used for dry skin conditions such as atopic eczema and psoriasis. Formulations include lotions, creams, gels, ointments, and sprays; and broadly are petroleum (paraffin) or non-petroleum based.

They are applied directly to the skin, typically

Visit link:
Burns with emollients - The BMJ

Dry skin is a problem year-round in Colorados arid climate, but in the wintery months, people especially feel the effects of lack of moisture. Photo: Getty Images.

Dry skin. Its a year-round problem in Colorado that, unfortunately, ratchets up even more in the dry, winter months.

A combination of factors in Colorado such as wind, low humidity, and high altitude can deplete skin of moisture, causing it to feel dry and itchy and also look dry and weathered. Additionally, with cold weather comes indoor heating, which causes dry skin in winter.

Turning on the heat circulates more dry air, which can be a skin irritant, explains Dr. Cory A. Dunnick, a dermatologist at UCHealth Dermatology Clinic Anschutz Medical Campus and professor of dermatology at the University of Colorado Department of Dermatology.

Dry skin can itch, turn red, flake, crack, and even bleed. Fortunately, there are ways to combat dry skin. Dr. Dunnick says the two main strategies are less soap and more moisturizer. Soaps are drying and moisturizers are hydrating. Here, she shares more ways to improve the way your skin looks and feels this winter.

Its not a bad idea to change your normal skin care routine in the winter. If you usually use a moisturizing lotion for your face and body, consider using a cream or ointment. Lotions are high in water content and the easiest formulation to rub into the skin but are less moisturizing than thicker creams. Ointments are oil-based and are the most moisturizing, says Dunnick. Look for products that contain:

Dunnick also recommends using a mild cleanser, especially for older adults. When youre young, a strong cleanser can help fight the acne that often accompanies puberty and the excess oil production that comes with it. However, as you age, you gradually produce less oil.

Older individuals need to revert to milder skin care products and dont need to use soap all over only in the smelly areas and can rinse with water in the shower, says Dunnick.

And dont skip the sunscreen. Just because its cold does not mean the sun is not strong.

In general, Dunnick says, the fewer the ingredients, the better. This advice goes for skin care products as well as laundry detergents and fabric softeners. For example, she recommends avoiding products with harsh preservatives, fragrances, or dyes.

If anti-aging products such as retinol and alpha-hydroxy acid (AHA) are part of your everyday skin care routine, you may want to give them a rest or cut down on how often you use them if you experience excessive dryness, redness, and flakiness. You should also avoid products with alcohol, except hand sanitizer, and limit how often you use an exfoliating scrub or product.

Cold weather and hot showers go together. Theres no need to eliminate that combo but try to shorten or limit your hot showers since hot water depletes the oil in your skin and also dries it out. Then, after your shower, generously apply moisturizer to your body and face immediately after drying off. This helps trap the moisture in your skin.

If youre fortunate enough to have access to a hot tub, the same advice goes for that hot water exposure. But, first, rinse off after soaking to wash away the chemicals that keep the hot tub water clean but can dry and irritate your skin.

Another way to generate heat in the cold weather is to light a fire. Unfortunately, the heat from a fire also tends to dry out the skin. Warm up with fleece and hot cocoa or tea instead. To combat the dry air caused by indoor heating, use a humidifier to add humidity to the air.

Did we mention that you should use a moisturizer? In addition to regularly applying moisturizer to your body, be sure to do the same for your hands and lips, two areas that often get chapped and irritated in the winter. These days, with all the handwashing and alcohol-based sanitizers people are doing to protect themselves from COVID-19, dry hands are especially problematic.

To prevent or alleviate excess dryness in your hand, be sure to wash your hands with lukewarm water and a mild cleanser, when possible, and apply moisturizer frequently. As for your lips, Dunnick recommends wearing a lip balm with SPF when outdoors. And contrary to what you may have heard, drinking water does not help relieve dry skin.

Increasing water intake does not improve skin hydration, says Dunnick. Instead, moisturize and use less soap.

While a moisturizer can help treat most cases of dry skin, it cant treat all dry skin. Your dry, itchy skin may be the result of a skin condition such as eczema or an underlying health condition such as kidney disease or hypothyroidism. Eczema is a common skin condition, affecting more than 31 million Americans. Symptoms include dry, itchy, inflamed, and cracked skin.

While moisturizer may relieve some eczema symptoms, eczema is a chronic skin condition that requires a treatment plan and possibly prescription medication. If home-care remedies fail to relieve dry skin after two weeks, make an appointment with a dermatologist.

Go here to read the rest:
Do these 2 things to tame dry skin in winter - UCHealth Today

I grew up convinced that any moisturizer not labeled oil free would clog the hell out of my pores; thankfully, if the slugging trend on TikTok is any indication, kids these days are not afraid of a little moisture in their skincare.

And they shouldnt be! For a long time people thought petrolatum was comedogenicthat is, it causes skin to clog up, says Michelle Wong, a cosmetic chemist and science educator based in Sydney, Australia. This was based on some studies on rabbit ears, where scientists applied petrolatum to them and counted clogged pores. But the study was faulty, she says: Rabbit ears are more sensitive than human skin and have larger pores that appeared clogged to the researchers. But the damage was done. This was eventually corrected in the mid-90s, when petrolatum was tested on human skin and found not to clog pores. But by then petrolatums reputation for pore-clogging was already established.

There are particular situations in which the heavy occlusivity of petroleum jelly products may do more harm than good. If youre using other especially strong, active skincare products before your moisturizer (for example, a retinoid), petrolatum can seal it inwhich in theory sounds like a great idea, but for folks with sensitive skin, the increased contact between your skin and the active ingredient can cause irritation. This irritation, says Wong, can lead to breakouts. So in a roundabout way, petrolatum can sometimes end up clogging pores, even if it isnt comedogenic on its own, she says.

You also definitely dont want to slug if you have any skin infections, says Boull. If you have impetigo, other bacterial infections of the skin, fungal infections of the skinthose would be times when you would want to steer clear of petrolatum, just until that infection got treated, she says. I asked her if that meant I shouldnt use it on the poison ivy I for some reason get every summer. It certainly wouldnt do much good, but it wouldnt hurt, either, she says, provided that I had thoroughly cleaned it before application. In that situation, she says, I should probably stick with a topical steroid for best results.

Read the original post:
Slugging Could Be the Secret to Healing Dry Winter Skin - ConsumerReports.org

The most common symptom of atopic dermatitis is itching, which can be severe. Other common symptoms include:

The symptoms can flare in multiple areas of the body at the same time and can appear in the same locations and in new locations. The appearance and location of the rash vary depending on age; however, the rash can appear anywhere on the body.

During infancy and up to 2 years of age, it is most common for a red rash, which may ooze when scratched, to appear on the:

Some parents worry that the infant has atopic dermatitis in the diaper area; however, the condition rarely appears in this area.

During childhood, usually 2 years of age to puberty, it is most common for a red thickened rash, which may ooze or bleed when scratched, to appear on the:

During the teenage and adult years, it is most common for a red to dark brown scaly rash, which may bleed and crust when scratched, to appear on the:

Other common skin features of atopic dermatitis include:

In addition, people with atopic dermatitis often have other conditions, such as:

Researchers continue to study why having atopic dermatitis as a child can lead to the development of asthma and hay fever later in life.

Complications of atopic dermatitis can happen. They include:

See the rest here:
Atopic Dermatitis Treatment, Symptoms & Causes | NIAMS

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

Eczema or atopic dermatitis is a condition that causes a person to develop patches of dry, itchy skin on their body. It often develops as a result of inflammation in the body, so eating foods that do not cause inflammation may help reduce symptoms.

While no cure exists, over-the-counter creams and medications that can help to reduce inflammation are available. Sometimes, a doctor may recommend avoiding foods known to make eczema worse.

Some foods may trigger the release of T cells that cause inflammation, as well as immunoglobulin-E or IgE, which is an antibody that the body produces in response to a threat. Foods that contribute to inflammation include nuts, milk, and wheat.

For people with eczema, eating certain foods can trigger the body to release immune system compounds that cause inflammation, which, in turn, contributes to an eczema flare-up. An anti-eczema diet is similar to an anti-inflammatory diet.

Examples of anti-inflammatory foods include:

Eating more of these foods and cutting down on any trigger foods could help to reduce eczema flare-ups.

Food-sensitive eczema reactions will typically occur about 6 to 24 hours after a person eats a particular food. Sometimes, these reactions may be delayed even longer.

To determine what foods may be causing the reaction, a doctor will often recommend an elimination diet. This diet involves avoiding some of the most common foods known to cause eczema.

Before eliminating any foods, a person will need to slowly add each food type into their diet and monitor their eczema for 4 to 6 weeks to determine if they are sensitive to any particular food.

If a persons symptoms get worse after adding a particular food to the diet, they may wish to consider avoiding it in the future. If a persons symptoms do not improve when eliminating a food, they probably do not need to remove it from their diet.

Some common foods that may trigger an eczema flare-up and could be removed from a diet include:

A doctor may also recommend allergy testing. Even if a person is not allergic to a particular food, they may have sensitivity to it and could experience skin symptoms after repeat exposure. Doctors call this reaction food responsive eczema.

People with dyshidrotic eczema, which typically affects the hands and feet, may experience benefits from eating foods that do not contain nickel. Nickel is found in trace amounts in the soil and can, therefore, be present in foods.

Foods that are high in nickel include:

Some people with eczema also have oral allergy syndrome or sensitivity to birch pollen. This means they may have reactions to other foods, including:

People with eczema are more prone to oral allergy syndrome and should speak to their doctor if they have a pollen allergy or experience mild allergic reactions to the above foods.

Research has shown that taking probiotic supplements may reduce the symptoms of eczema. More studies are needed, however, to confirm the effectiveness and dosage required.

Probiotics are available in a variety of supplements, such as the selection available here. If a person is not sure which probiotics to buy, they may find the online reviews helpful and can also talk to their doctor.

Probiotics are also naturally present in many foods. Probiotic foods include:

Other supplements that have been studied include fish oil and Chinese herbal preparations; neither of which made a significant difference in eczema symptoms.

While a persons diet is not always a trigger for eczema, some people may find that their symptoms do get better when they make dietary changes.

Making these changes and monitoring the results can help a person determine whether changing their diet can help them better manage their condition.

If a person does eliminate a large food group, such as wheat-containing products, they may wish to talk to their doctor about supplements to ensure they are not missing out on any essential vitamins and minerals.

Read more:
Eczema diet tips: Foods to eat and avoid

On Jan. 14, AbbVie's (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn't respond to other medicines.

What led the FDA to approve Rinvoq for its third indication? And how much of a boost could this be for AbbVie's sales? Let's dig into the phase 3 clinical trial results and U.S. moderate-to-severe eczema market to find the answers to these two questions.

Image source: Getty Images.

According to Healthline, eczema is a chronic skin condition often expressed by patches of dry, inflamed, and itchy skin. It's thought that the disease is caused by excessive production of immune system cells that lead to inflammation. Eczema typically begins in early childhood and flares up from time to time.

Common first-line treatments for the condition include antihistamines and topical corticosteroids (TCS). Unfortunately, a majority of patients with moderate-to-severe eczema (55%) cannot control their eczema with their current treatment regimen. This can result in sleep issues and weigh on a patient's quality of life, which is why there's demand for more treatments for the disease.

Fortunately, more treatment options are making their way to the market. One of those treatments is Rinvoq, which was approved last August in the European Union to treat moderate-to-severe eczema.What data is there to support the approval in the EU and most recently in the U.S.?

Rinvoq funded a randomized clinical trial of 901 moderate-to-severe eczema patients. These patients were blindly assigned to either receive 15 milligrams of Rinvoq once daily with TCS, 30 milligrams of Rinvoq each day combined with TCS, or a placebo pill and TCS. The patients were followed over the course of a 16-week period. The more pronounced the reduction in the Eczema Area and Severity Index (EASI), the more effective a treatment was for eczema patients. The EASI is a clinical scale that measures eczema's severity and surface area. A 75% or greater improvement in the EASI is called EASI75, which is the best indication of whether a treatment is effective enough to be approved by regulatory agencies.

Patients taking TCS and the lower dose of Rinvoq were found to have reached at least 75% clearer skin, or EASI75, at a 65% rate at week 16, which was much higher than the 26% rate for the TCS and placebo group at week 16. Even more striking, 77% of patients receiving the higher dose of Rinvoq achieved EASI75 at week 16.

Rinvoq could be a powerful treatment for many patients with eczema. So, what could this mean for pharma stock AbbVie?

First, it's estimated that there are 6.6 million adults in the U.S. with moderate-to-severe eczema. For the sake of conservatism and sparse data being available, I won't include the population of U.S. adolescents with the disease.

Second, although 55% of moderate-to-severe eczema patients aren't satisfied with their treatment plan, I'll assume that approximately 20% of the patient pool could start Cibinqo.This works out to 1.3 million potential patients.

Third, Cibinqo has the benefit of being a pill, which helps patients avoid having to go into clinics and hospitals for injections to treat their condition. On the other hand, the convenience of Cibinqo could be at least partially offset by the fact that the drug is a Janus kinase inhibitor. Due to the increased risk of serious adverse events like blood clots, cancer, and major heart-related issues, the FDA could end up restricting patients to just the lower dose of Cibinqo for safety reasons.

Considering all of these factors, I believe that the drug could capture 6% of the market, or 79,000 patients.

Rinvoq has an annual list price of $68,000. Adjusting for patient assistance programs and negotiations from health insurers, I'll use $20,000 as the net annual price per patient. This equates to just under $1.6 billion in annual revenue potential.

Against the $59.8 billion in revenue that analysts are forecasting for AbbVie this year, this would be a nearly 3% boost to the company's overall revenue. An additional $1.6 billion in annual revenue for AbbVie would represent a 30%+ increase in the company's non-Humira immunology segment revenue over the nearly $4.6 billion in combined Skyrizi and Rinvoq revenue for last year.

AbbVie's 8.5% increase in the dividends per share that it will pay out to shareholders in 2022 brings its dividend increase streak to 50 consecutive years -- including its time as part of Abbott Laboratories. This makes the stock a Dividend King.

AbbVie is trading at a forward price-to-earnings (P/E) ratio of 9.8, which is an appealing valuation considering that the stock's earnings are expected to grow 5% annually in the next five years. Investors can scoop up shares of AbbVie and its market-trouncing, steady 4.1% dividend yield on the cheap. That's what makes the stock an attractive option for income investors at the current $140 share price.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

More:
AbbVie Wins Yet Another Approval for This Drug - Motley Fool

[90 Pages Report] Baby Ointment Market Insights 2022 This report contains market size and forecasts of Baby Ointment in United States, including the following market information:

United States Baby Ointment Market Revenue, 2016-2021, 2022-2027, (USD millions)

United States Baby Ointment Market Sales, 2016-2021, 2022-2027, (K Units)

United States top five Baby Ointment companies in 2020 (%)

The global Baby Ointment market size is expected to growth from USD million in 2020 to USD million by 2027; it is expected to grow at a CAGR of % during 2021-2027.

The United States Baby Ointment market was valued at USD million in 2020 and is projected to reach USD million by 2027, at a CAGR of % during the forecast period.

The Research has surveyed the Baby Ointment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19458710

Leading key players of Baby Ointment Market are

Baby Ointment Market Type Segment Analysis (Market size available for years 2022-2027, Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2027): Massage Oils, Lotions, Medicinal Creams

Regions that are expected to dominate the Baby Ointment market are North America, Europe, Asia-Pacific, South America, Middle East and Africa and others

If you have any question on this report or if you are looking for any specific Segment, Application, Region or any other custom requirements, then Connect with an expert for customization of Report.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19458710

For More Related Reports Click Here :

Cresylic Acid Market In 2022

Band Saw Blades Market In 2022

Go here to read the rest:
(New Report) Baby Ointment Market In 2022 : The Increasing use in Eczema, Heat Rash, Diaper Rash, Dry Skin, Cuts, Insect Bites is driving the growth...

Eli Lilly has made the difficult decision to cull a phase 3 study of Verzenio in HER2-positive early breast cancer, Dan Skovronsky, M.D., Ph.D., chief scientific and medical officer at Lilly, said on a call with investors Thursday.

Details were slim, but Skovronsky blamed the decision on changes in the treatment landscape plus global enrollment challenges.

Importantly, this decision does not change our commitment to an investment in breast cancer, Lillys chief scientist said.

News of the Verzenio trial halt comes a week after Lilly announced it was pulling the plug on Olumiants development in lupus. Separately, Olumiants application in moderate-to-severe atopic dermatitis could be in jeopardy, thanks to a stalemate with the FDA about the exact patient population, the company said last week. Lilly expects regulatory action on Olumiants eczema bid very soon, Skovronsky said Thursday.

RELATED:CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say

During the call,Lilly shed more light on Olumiants regulatory impasse in eczema. Lilly believes Olumiant benefits eczema patients most when used in early treatment, Patrik Jonsson, SVP and president of Lilly immunology and president of Lilly USA, said on the call. The FDA, conversely, currently has the position of saving Olumiant for the refractory patients, where we see the incremental value of Olumiant to be quite limited.

If that doesnt change, a complete response letter is likely, Jonsson said.

Lilly has also submitted Olumiant for approval in alopecia, though ananalyst on Wednesdays call questioned whether safety concerns around the JAK-inhibitor class at large could blunt the drugs ambitions there. Lilly simply said it was encouraged by the data its seen so far, and it highlighted the immense opportunity in the disease.

There are currently no treatments approved for alopecia areata, Jonsson said. We have the opportunity here to be first in disease with Olumiant.

There are about 360,000 patients diagnosed with alopecia in the U.S., some 100,000 of whom would be eligible for treatment with a JAK inhibitor, Jonsson added.

RELATED:UPDATED: Eli Lilly to plow a total of $1.5B into 2 new manufacturing plants

For the fourth quarter, Eli Lillys revenue jumped 8% to $7.9 billion. Excluding COVID-19 antibodies, sales for the last three months of the year climbed 6%. Full-year sales increased 15% to $28.3 billion or 10% after subtracting Lillys pandemic antibodies from the equation.

Last month, The FDAtweakedits emergency nod for Lilly and Regenerons monoclonal antibodies, citing recent data showing the drugs arent effective against omicron. The antibodies are now limited to patients whove been infected with or exposed to a variant susceptible to the therapies.

Lilly snared $1.1 billion in COVID-19 antibody revenue for the fourth quarter. Lilly says it delivered roughly 435,000 doses out of 614,000 in the last three months of the year, with most of the remaining doses already shipped out last month.

Lilly credited its fourth-quarter momentum to growth drugs like Trulicity, Taltz, Verzenio, Olumiant, Emgality and more.

"Lillys margin profile represents one of the strongest expansion stories in Pharma, in our opinion, with the potential for mid-teens EPS growth, Cantor Fitzgerald analyst Louise Chen wrote in a note to clients Thursday. Her team thinks Lilly is poised to enter a growth period through 2030, helped by multiple readouts for products like donanemab in Alzheimers disease and tirzepatide in Type 2 diabetes.

Lilly has forecasted full-year 2022 sales between $27.8 billion and $28.3 billion.

View post:
Eli Lilly nixes Verzenio's phase 3 HER2-positive early breast cancer trial - FiercePharma

LEO Pharma announced new 16-week data on tralokinumab-ldrm, stating that it led to significant improvements in itch, sleep interference, anxiety and depression, and overall quality of life among adolescents aged 12-17 years old with moderate-to-severe atopic dermatitis.

The data were presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) 59th Annual Scientific Session in Maui.

Tralokinumab-ldrm was previously approved by the US Food and Drugs Administration (FDA) in December 2021 for the treatment of adults with moderate-to-severe atopic dermatitis. It is the first and only FDA approved biologic that binds to and inhibits the interleukin (IL)-13 cytokine.

The most recent analysis evaluated patient-reported outcomes with the biologic compared to placebo at week 16 during the 52-week monotherapy phase 3 ECZTRA 6 trial.

A total of 100 patients received 150 mg of tralokinumab-ldrm, while 101 received 300 mg of the biologic. Investigators observed that siginificantly more adolescent patients achieved improvements with the biologic every 2 weeks compared to the 100 patients who received placebo.

A 4-point improvement in adolescent Worst Daily Pruritus Numeric Rating Scale (NRS) was seen in 23.2% of patients receiving tralokinumab-ldrm 150 mg (P<0.001), 25.0% of those in the tralokinumab-ldrm 300 mg group (P<0.001), and 3.3% placebo, while a 6-point improvement in Childrens Dermatology Life Quality Index (CDLQI) was recorded in 31.0% of patients receiving tralokinumab-ldrm 150 mg (P=0.029), 39.5% tralokinumab-ldrm 300 mg (P<0.001), and 15.9% placebo.

Additionally, a 6-point improvement in Patient Oriented Eczema Measure (POEM) was reported in 38.7% of the tralokinumab-ldrm 150 mg group (P<0.001), 46.8% of the tralokinumab-ldrm 300 mg group, (P<0.001), and 10.5% of the placebo group. The biologic was also associated with greater improvement than placebo in eczema-related sleep NRS.

Currently, Tralokinumab-lfrm is not FDA approved in adolescents, and its efficacy and safety have not been full evaluated.

Read more here:
Tralokinumab Linked to Overall Quality of Life Improvements in Adolescents with AD - MD Magazine